Phase I/II study of Second-lIne therapy of preoperative cheMoradiothERApy with gemcitabine and nab-paclitaxel for locally advanced pancreatic canceR (SIMERAR trial) - Phase I/II study of Second-lIne therapy of preoperative cheMoradiothERApy with gemcitabine and nab-paclitaxel for locally advanced pancreatic canceR (SIMERAR trial)

Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama0 个研究点目标入组 45 人开始时间: 2022年2月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Active multiple cancers 2) Patients whose dose of GEM+nab-PTX in primary chemotherapy was reduced to less than 600 mg/m2 of GEM or less than 75 mg/m2 of nab-PTX 3) Patients who were refractory or intolerant to primary GEM+nab-PTX and were switched to other chemotherapy 4) Infection or inflammation that requires systemic treatment 5) Fever of 38.0 degrees Celsius higher at the time of registration 6) Allergy or contraindication to gemcitabine or paclitaxel 7) History of severe drug hypersensitivity or drug allergy 8) Allergy to contrast media 9) History of serious heart disease 10) History of serious underlying diseases (poorly controlled diabetes, renal failure, liver cirrhosis, etc.) 11) Poorly controlled ascites or pleural effusion 12) Active gastrointestinal bleeding requiring repeated blood transfusions. 13) Diarrhea (more than 4 times a day or watery stools) 14) Poorly controlled cancer pain 15) Pulmonary fibrosis or interstitial pneumonia with obvious or clinical findings on imaging 16) Lung field enters the radiation field 17) Pregnant or lactating women or those with the potential (intention) to become pregnant 18) Severe psychological or neurological disease 19) Unable to give consent to participate in this study

发起方

Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama